NCT06802666 is a Phase 2 clinical trial of short-course radiotherapy in Locally Advanced Rectal Cancer, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT06802666?

Interventions in NCT06802666: short-course radiotherapy, Ivonescimab, capecitabine, oxaliplatin, TME surgery.

What condition does NCT06802666 study?

NCT06802666 studies Locally Advanced Rectal Cancer, Neoadjuvant Therapy.

Is NCT06802666 still recruiting?

NCT06802666 is currently recruiting now. Last updated 31 January 2025.

Last reviewed 2025-01-31 · How we verify

NCT06802666

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Recruiting now Phase 2 Last updated 31 January 2025

What this trial tests

Phase 2 trial testing short-course radiotherapy in Locally Advanced Rectal Cancer in 45 participants. Currently enrolling.

Timeline

16 October 2024

Primary endpoint
1 September 2026

30 December 2027

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	16 October 2024
Primary completion	1 September 2026
Estimated completion	30 December 2027
Sites	1 location across China

Drugs / interventions tested

short-course radiotherapy
Ivonescimab — full drug profile →
capecitabine (capecitabine) — full drug profile →
oxaliplatin (Oxaliplatin) — full drug profile →
TME surgery

Conditions studied

Locally Advanced Rectal Cancer — all drugs for Locally Advanced Rectal Cancer →
Neoadjuvant Therapy — all drugs for Neoadjuvant Therapy →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 75, any sex, with Locally Advanced Rectal Cancer or Neoadjuvant Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the efficacy and safety of short-course radiotherapy followed by AK112 in combination with CAPOX as neoadjuvant therapy in patients with locally advanced rectal cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Spatiotemporal dynamics of radioresistance: decoding macrophage-driven radioprotective niches through temporal-spatial reprogramming.
Zhang M, Zhang X, Song X, Bai R, et al · · 2026 · PMID 41776613 · DOI 10.1186/s12943-026-02598-6

Verify or expand the search:

Other trials of short-course radiotherapy

Trials testing the same drug.

NCT07243938 — Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) · Phase 2 · not yet recruiting
NCT05673772 — Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer · Phase 2 · active not recruiting

Other recruiting trials for Locally Advanced Rectal Cancer

Currently open trials in the same condition.

NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting
NCT07150949 — Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MS · Phase 2 · recruiting
NCT07057089 — Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) · Phase 2 · recruiting
NCT06894797 — Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. · NA · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06802666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 31 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06802666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing